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Introduction: Weight loss has been described in 20% to 45% of patients with Alzheimer’s disease (AD) and has
been associated with adverse outcomes. Various mechanisms for weight loss in AD patients have been proposed,
though none has been proven. This study aimed to elucidate a mechanism of weight loss in AD patients by
examining the hypothesis that weight loss is associated with medial temporal lobe atrophy (MTA).
Methods: Patients from the Frisian Alzheimer’s disease cohort study (a retrospective, longitudinal study of 576
community-dwelling AD patients) were included when a brain MRI was performed on which MTA could be
assessed. To investigate the hypothesis that weight loss is associated with MTA, we investigated whether the
trajectory of body weight change depends on the severity of MTA at the time of diagnosis (that is baseline).
We hypothesized that patients with more severe MTA at baseline would have a lower body weight at baseline
and a faster decrease in body weight during the course of the disease. The generalized linear mixed model
(GLMM) was used to determine the relationship of weight change trajectory with MTA severity.
Results: In total, 214 patients (median age 79 years, median MMSE 23, mean weight 73.9 kg) were included.
Patients with moderate, severe or very severe MTA at baseline weighed 3.2 to 6.8 kg more than patients with
no or mild MTA. During the 3.5 years, patients gained on average 1.7 kg in body weight, irrespective of the
severity of their MTA at baseline.
Conclusions: We found no evidence that MTA is associated with weight loss in AD patients. Moreover,
contrary to what was expected, AD patients did not lose but gained weight during follow-up.Introduction
Various studies have investigated the relationship be-
tween body weight and Alzheimer’s disease (AD). On
the one hand, being overweight has been associated with
poorer cognitive function [1] and has been described as
a risk factor for AD [2]. On the other hand, in 1907,
Alois Alzheimer described weight loss in his first patient
[3] and weight loss is currently recognized as a clinical
feature of AD [4]. In the present study, we will focus on
the relationship between weight loss and AD.
Weight loss has been described in approximately 20% to
45% of patients with AD [5-11] and has been associated* Correspondence: erika.droogsma@znb.nl
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unless otherwise stated.with adverse outcomes such as an accelerated progression
of AD [5,7,11,12], a higher rate of institutionalization [13]
and increased mortality [14-16]. Various mechanisms of
weight loss in AD patients have been proposed [5,17-19],
though, none has been proven.
The regulation of body weight is complex and influ-
enced by various factors such as appetite, feeding behav-
ior and endocrine systems [20,21]. In addition, it is
supposed that different brain areas are involved, one of
which is the medial temporal lobe, possibly by influen-
cing food intake and appetite [22-24]. Moreover, atrophy
of the medial temporal lobe reflects changes in func-
tional neuroanatomical networks that are involved in the
regulation of body weight [22]. The medial temporal
lobe is a site where AD pathology is typically present
[25]. On magnetic resonance imaging (MRI), it shows at-
rophy in the earliest stages of the disease, which worsenstral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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medial temporal lobe atrophy (MTA) was associated
with low body weight in AD patients [22]. Because of
the cross-sectional design it was not possible to attribute
cause and effect relations in this study, that is, weight
loss may be a result of MTA or conversely, aggravate MTA
[17,22]. If the latter is true, weight gain, for example by
providing nutritional interventions, might prevent or slow
MTA and possibly disease progression.
Few studies investigated the relationship between brain
pathology and nutritional status in AD patients. The
results of these studies are conflicting and none of the
studies focused primarily on the relationship between
MTA and nutritional status [26-28]. The aim of the present
study was to elucidate a mechanism of weight loss in AD




This study was conducted with data from the Frisian
Alzheimer’s disease cohort study, a retrospective, longi-
tudinal study of the long-term course of 576 AD patients
seen at a large memory clinic in the north of the
Netherlands. Patients were evaluated by a physician and
a specialized geriatric nurse who performed a compre-
hensive geriatric assessment (CGA) [29]. When a diag-
nosis of AD could not be established based on the CGA
and cognitive screening tests, additional tests were or-
dered, including brain imaging, with MRI as the pre-
ferred imaging technique [30,31]. When the diagnosis of
probable or possible AD (according to the criteria of the
National Institute of Neurological and Communicative
Diseases - Alzheimer’s Disease and Related Disorder
Association (NINCDS-ADRDA)) [4] was established,
patients were offered pharmacological (that is, cholin-
esterase inhibitors (ChEIs) and/or memantine) and non-
pharmacological interventions (that is case management,
respite care, meals at home services). Yearly outpatient
visits were scheduled to evaluate the overall condition of
the patient, including body weight, and the effect of the
interventions. Outpatient visits ended when pharmaco-
logical treatment was terminated or in the case of nursing
home admission. The total number of outpatient visits for
patients from the Frisian Alzheimer’s disease cohort study
ranged from one to eleven, the median number was three
(that is 1.5 years) (25th to 75th percentile 2 to 5).
Participants and study design
Patients included in the Frisian Alzheimer’s disease cohort
study visited the memory clinic between 2002 to 2012,
were 65 years or older, lived at home or in residential care
at the time of diagnosis and started with a ChEI. Patients
were included in the present study when they had abaseline assessment, at least one follow-up assessment
and a MRI of the brain (performed up to 6 months
prior to AD diagnosis) on which MTA could be
assessed. To examine the hypothesis that weight loss is
associated with MTA, we investigated whether the tra-
jectory of body weight change depends on the severity
of MTA at the time of diagnosis (that is baseline). We
hypothesized that patients with more severe MTA at
baseline would have a lower body weight at baseline
and a faster decrease in body weight during the course
of the disease. This study, for which informed consent
was not required, was approved by the local ethics com-
mittee of the Medical Center Leeuwarden. Informed con-
sent was not required because this was a retrospective




Age, gender, social status, use of informal and of profes-
sional care (that is household help, meals at home ser-
vices) were recorded. Comorbidity was evaluated by the
cumulative illness rating scale (CIRS) with total scores
ranging from 0 (no impairment) to 56 (extremely severe
impairment) [32]. AD as the index disease was not
included in the CIRS score. The number of medications
beside the ChEI was recorded. Polypharmacy was
defined as use of four or more medications beside the
ChEI.
Cognitive functioning
Cognitive functioning was assessed by the mini mental
state examination (MMSE) [33] and the clock-drawing
test (CDT). The CDT was scored according the scoring
system of Shulman et al. in 1993, in which the total score
ranges from 1 to 6, and a score of 3 or more indicates
cognitive impairment [34].
Behavioral and psychological symptoms (BPS) of dementia
Based on self-reported patient and caregiver information,
we recorded whether BPS were present or absent. Since BPS
were not operationalized with a measurement instrument, it
was not possible to report the severity, nature or frequency
of BPS.
Type and dosage of ChEI
At each outpatient visit, type and dosage of ChEI, and
if applicable memantine, were recorded. At our memory
clinic, galantamine retard is the first choice of treatment
for patients with mild to moderate AD. The retard form
of galantamine has been prescribed since 2005. Before 2005,
galantamine was given twice daily. The dose is gradually
increased from 8 milligram (mg) per day to 24 mg per day
in 8 weeks.
Table 1 Patient characteristics at baseline
Age (year): n, median [25th -75th percentile] 214, 79 [75 - 82]
Women, n (%) 132 (61.7)
Social status
alone, n (%) 93 (44.9)
with partner, n (%) 108 (52.2)
other*, n (%) 6 (2.9)
CIRS (score): n, median
[25th -75th percentile]
214, 6.0 [4.0- 8.0]
Number of medications beside ChEI
≤4, n (%) 100 (46.9)
>4 (polypharmacy), n (%) 113 (53.1)
Use of informal care, n (%) 182 (85.4)
Use of professional care, n (%) 99 (46.9)
MMSE (score): n, median
[25th -75th percentile]
212, 23 [20 - 25]
MMSE score ≤24, n (%) 138 (65.1)
MMSE >26, n (%) 33 (15.6)
Mild AD (MMSE 21 - 26), n (%) 126 (59.4)
Moderate AD (MMSE 10 - 20), n (%) 53 (25.0)
Moderate severe AD (MMSE 10 - 14), n (%) 3 (1.4)
Severe AD (MMSE <10), n (%) 0 (0)
Clock-drawing test (score): n, median
[25th -75th percentile]
193, 3.0 [2.0 - 4.5]
Clock-drawing test score ≥3, n (%) 140 (72.5)
Presence of BPS, n (%) 51 (24.4)
ChEI which was started
galantamine, n (%) 209 (97.7)
rivastigmine, n (%) 5 (2.3)
Weight (kg): n, mean ± SD 214, 73.8 ± 12.0
BMI (weight/(height)2): n, median
[25th -75th percentile]
203, 25.8 [23.5 - 28.6]
Use of ONS, n (%) 1 (0.5)
Appetite
good, n (%) 170 (92.9)
poor, n (%) 13 (7.1)
Self-reported weight loss, n (%) 28 (14.4)
Left MTA score
0 (no atrophy), n (%) 1 (0.5)
1 (mild atrophy), n (%) 15 (7.0)
2 (moderate atrophy), n (%) 111 (51.9)
3 (severe atrophy), n (%) 65 (30.4)
4 (very severe atrophy), n (%) 22 (10.3)
Right MTA score
0 (no atrophy), n (%) 2 (0.9)
1 (mild atrophy), n (%) 15 (7.0)
Table 1 Patient characteristics at baseline (Continued)
2 (moderate atrophy), n (%) 108 (50.5)
3 (severe atrophy), n (%) 74 (34.6)
4 (very severe atrophy), n (%) 15 (7.0)
*Other, that is: with son or daughter, brother or sister. n, number of patients;
CIRS, cumulative illness rating scale; ChEI, cholinesterase inhibitor; MMSE, mini
mental state examination; AD, Alzheimer’s disease; BPS, behavioral and
psychological symptoms; SD, standard deviation; BMI, body mass index; ONS,
oral nutritional supplement; MTA, medial temporal lobe atrophy.
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Body weight (kg), body mass index (BMI), self-reported
weight loss, appetite and use of oral nutritional supplements
(ONS) were recorded. Self-reported weight loss, appetite and
use of ONS were recorded based on patient and caregiver
information.
Medial temporal lobe atrophy (MTA)
Brain MRIs were obtained with a Philips 3.0 Tesla MRI
scanner (Philips, Eindhoven, the Netherlands). MTA was
assessed on coronal three-dimensional gradient T1-weighted
MRI sequences. MTA was rated using a validated 5-point
visual rating scale, based on the evaluation of the width
of the choroidal fissure, the width of the temporal horn
and the hippocampal height [35,36]. The severity of
MTA was scored from 0 (no atrophy) to 4 (very severe
atrophy) [35]. According to the instructions of the visual
rating scale, both left and right MTA were examined
[37,38]. MTA was scored independently by two raters (ED
and HB, both research fellows) who were trained in rating
MTA by an experienced neurologist. The agreement
between the two raters was measured by calculating the
kappa value [39]. Disagreement between ED and HB was
resolved by discussion with a third rater (DA).
Statistical analysis
Data were analyzed with the Statistical Package for
the Social Sciences (SPSS) 16.0 (SPSS Inc., Chicago, IL,
USA) and Statistical Analysis Software (SAS) 9.2 (SAS
Institute Inc., Cary, NC, USA). Hypotheses were two-
tailed tested. A probability (P) value of less than 0.05
was considered statistically significant. Descriptive statis-
tics are presented as mean ± standard deviation (SD) for
normally distributed variables. For skewed distributed
variables, median and 25th to 75th percentiles are given.
We used the Kolmogorov-Smirnov test to establish the
distribution of the variable. Number and proportion are
given for categorical variables.
To investigate whether the trajectory of body weight
change depends on the severity of MTA at baseline, the
trajectory of body weight change was compared between
MTA score groups, using the generalized linear mixed
model (GLMM) [40,41]. The GLMM has been devel-
oped for the analysis of longitudinal, dependent data and
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(that is body weight) over time. The GLMM analyses
were performed with data from patients with a baseline
assessment and at least one follow-up assessment. Other-
wise, it is not possible to describe a change in body weight
over time. Scores of left and right MTA were used separ-
ately for analyses. From the sixth (left MTA), respectively
the fifth (right MTA) measurement moment, it was not
possible to give a reliable estimate of change in body
weight due to the small number of remaining patients at
that moment. Therefore, the GLMM analyses were per-
formed on the first five measurement moments (a period
of 3.5 years) for left MTA scores, respectively on the first
four measurements (a period of 2.5 years) for right MTA
scores.
The relationship of left MTA and right MTA with the
trajectory of weight was analyzed in a multivariate
GLMM, including potential confounders. The multivari-
ate GLMM analyses were performed according the
backward-method with weight as the primary outcome
(that is the dependent variable). MTA group, time (that
is the number of measurement moments) and the poten-
tial confounders were used as independent variables.
Potential confounders were baseline variables associ-
ated with the course of weight in univariate GLMM ana-
lysis, it involved: gender (P <0.001), social status (P = 0.048),
informal care (P = 0.003) and self-reported weight loss
(P <0.001). To correct for potential interactions, we in-
vestigated whether there were interactions of left MTA
and right MTA score with time or with the four poten-
tial confounders.
Various baseline characteristics were compared between
patients with a MTA score of 0 or 1 versus a MTA score
of 2, 3 or 4. The independent sample t test was performed
to compare normally distributed variables. We employed
the Mann-Whitney U test to compare skewed distributed
variables. Pearson chi-square or Fisher’s exact test were
used to compare categorical variables.Table 2 Number of patients with weight loss, weight gain or
No change in weight: n, (%)
Between baseline 6 (3.1)
and 6 months
Between 6 months 7 (5.0)
and 18 months
Between 18 months 4 (3.8)
and 30 months
Between 30 months 3 (4.1)
and 42 months
n, number of patients; SD, standard deviation.Results
Patient characteristics at baseline
Two hundred and fourteen patients were included. At
baseline, median age was 79 years (25th to 75th percent-
ile 75.0 to 82.0), median MMSE score 23 (25th to 75th
percentile 20.0 to 25.0) and mean weight 73.8 ± 12.0 kg.
More than half of the patients had mild AD and none of
the patients had severe AD. Almost one in every six pa-
tients reported weight loss (14.4%) and thirteen patients
(7.1%) had a poor appetite (Table 1). An additional table
summarizes the number of patients who experienced weight
loss, weight gain or no change in weight (Table 2).
Medial temporal lobe atrophy (MTA)
The MRI scans were performed median 20.5 days (25th
to 75th percentile 45.0 to 8.0) before the diagnosis AD
was made. Three patients (1.4%) had a MTA score of 0
(Table 1), they were clustered with patients with a MTA
score of 1, representing patients with no or mild MTA. In
75.4% of the patients, the MTA of the left side was the
same as on the right side. The agreement between the two
raters was fair to good for left MTA (Cohen’s kappa 0.66)
and fair for right MTA (Cohen’s kappa 0.60) [39,42].
Relationship of left MTA with the trajectory of weight
change
The trajectory of weight change for left MTA score is
presented in Table 3 and Figure 1. During the first
6 months, body weight decreased with 0.4 kg in all MTA
groups (Table 3, Figure 1). Thereafter, it increased grad-
ually with 2.1 kg in the subsequent 3 years (Figure 1,
Table 3). Overall, all patients gained on average 1.7 kg in
body weight during 3.5 years (Table 3, Figure 1). Figure 1
and Table 3 show an obvious difference in body weight
between patients with a MTA score of 0 or 1, versus pa-
tients with a MTA score of 2, 3 or 4 (Table 3, Figure 1).
Because of this clear difference with a highly compar-
able trajectory of weight in patients with MTA score 2,no change in weight over time
Weight loss: n, (%) mean
weigh loss (kg) ± SD
Weight gain: n, (%) mean
weight gain (kg) ± SD
101 (52.6) 85 (44.3)
−2.9 ± 2.7 2.5 ± 2.3
53 (37.6) 81 (57.4)
−2.7 ± 2.2 2.7 ± 2.4
41 (38.7) 61 (57.5)
−2.1 ± 1.4 2.6 ± 1.8
28 (38.4) 42 (57.5)
−3.1 ± 3.9 3.6 ± 4.6
Table 3 Trajectory of weight per left MTA score (results from the univariate GLMM analyses)
n MTA score 0 or 1 MTA score 2 MTA score 3 MTA score 4
mean weight (95% CI) mean weight (95% CI) mean weight (95% CI) mean weight (95% CI)
Baseline 214 67.44 (61.87 - 73.01) 74.67 (63.17 - 86.17) 73.27 (61.51 - 85.03) 75.59 (62.71 - 88.47)
6 months 194 67.02 (60.97 - 73.08) 74.25 (62.26 - 86.25) 72.85 (60.60 - 85.11) 75.17 (61.80 - 88,54)
18 months 160 67.60 (61.32 - 73.88) 74.83 (62.62 - 87.04) 73.43 (60.96 - 85.91) 75.75 (62.16 - 89.34)
30 months 116 68.18 (61.80 - 74.57) 75.42 (63.09 - 87,74) 74.01 (61.43 - 86.60) 76.33 (62.63 - 90.04)
42 months 79 69.15 (62.18 - 76.12) 76.38 (63.48 - 89.28) 74.98 (61.81 - 88.14) 77.30 (63.01 - 91.58)
MTA, medial temporal lobe atrophy; GLMM, generalized linear mixed model; n, number of remaining patients; CI, confidence interval.
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patients with a MTA score of 0 or 1, versus patients
with a MTA score of 2, 3 or 4 (Table 4, Figure 2).
Patients with MTA 0 or 1 weighed 6.8 kg less than
patients with MTA 2, 3, 4 at every moment during
follow-up, independent of potential confounders (P =
0.001). There were no interactions of the left MTA
score with time or with the four potential confounders.
As shown in Table 5, patients with MTA 0 or 1 were
younger and had a higher MMSE score at baseline
compared to patients with a MTA score of 2, 3 or 4
(Table 5).
Relationship of right MTA with the trajectory of weight
change
The trajectory of weight per right MTA score is pre-
sented in Table 6 and Figure 3. As for the left MTA, we
compared the trajectory of weight between patients with
a MTA score of 0 or 1, versus patients with a MTA
score of 2, 3 or 4 (Table 7, Figure 4). Patients with MTA
0 or 1 weighed less than patients with MTA 2, 3, 4 at
any moment during follow-up. In this, an interaction
with time (P = 0.001) was observed, depending on the
moment during follow-up, patients with MTA 0 or 1Figure 1 Trajectory of weight per left MTA score (results from the un
MTA, medial temporal lobe atrophy.weighed between 3.2 kg (at 6 months) and 6.4 kg (at
18 months) less than patients with MTA 2, 3, 4 (Table 7,
Figure 4). Overall, all patients gained on average 0.7 kg
in body weight after 2.5 years (Table 7). As for the left
MTA, we compared the baseline characteristics between
patients with MTA 0 or 1, versus patients with a MTA
score of 2, 3 or 4 (Table 8). Patients with MTA 0 or 1
were younger, had a higher MMSE score and used infor-
mal care less often at baseline compared to patients with
a MTA score of 2, 3 or 4 (Table 8).
Discussion
The aim of the present study was to elucidate a mechan-
ism of weight loss in AD patients. Contrary to what
was expected, AD patients in our population did not
lose, but gained weight during the 3.5 years of follow-up.
Recent studies have reported similar results [43,44].
Secher et al. showed that community-dwelling patients
with moderate AD did not lose weight during 4 years of
follow-up [43], Gu et al. showed that after the clinical
onset of AD, BMI increased [44]. How can the increase
in body weight be explained?
The number of community-dwelling AD patients with
weight loss described in the literature, varies betweenivariate GLMM analyses). GLMM, generalized linear mixed model;
Table 4 Trajectory of weight: left MTA 0 or 1 versus 2, 3 or 4 (results from the univariate GLMM analyses)
n MTA score 0 or 1 MTA score 0 or 1 MTA score 2, 3, 4 MTA score 2, 3, 4
mean weight (95% CI) Δ Weight mean weight (95% CI) Δ Weight
Baseline 214 67.49 (61.91 - 73.07) 74.31 (62.95 - 85.67)
6 months 194 67.07 (61.00 - 73.14) −0.42 73.89 (62.05 - 85.74) −0.42
18 months 160 67.65 (61.36 - 73.94) 0.58 74.47 (62.40 - 86.54) 0.58
30 moths 116 68.24 (61.84 - 74.63) 0.59 75.06 (62.88 - 87.23) 0.59
42 months 79 69.19 (62.21 - 76.17) 0.95 76.01 (63.26 - 88.77) 0.95
MTA, medial temporal lobe atrophy; GLMM, generalized linear mixed model; n, number of remaining patients; CI, confidence interval.
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in studies from the pre-ChEI era [5,6,9], and recent
studies showed a decreased risk of weight loss in AD
patients treated with a ChEI compared to untreated
patients [7,8,45,46]. In these studies, ChEIs appeared to
protect against weight loss. Therefore, the weight gain in
our cohort might be explained by the use of a ChEI.
It could be that weight loss in AD patients is currently
less frequently observed due to the increased quality of
care of home-dwelling AD patients. In the past decade,
it is not just the pharmacological treatment that has
changed the management of AD. Drugs are given in
addition to multiple non-pharmacological interventions,
including dietary advice and provision of meals at home
services [31,47]. Gu et al. showed that the BMI of AD
patients declined up to the clinical onset of AD. After
clinical onset, there was no decrease of BMI, which even
increased, possibly because care was arranged after the
diagnosis of AD [44]. We postulate that weight loss in
AD patients could be regarded as a marker for the qual-
ity of care for AD patients, rather than a marker for the
severity of AD. This is underpinned by our finding that
the severity of AD, measured by the severity of MTA,
was not related to the trajectory of weight.Figure 2 Trajectory of weight; left MTA score of 0 or 1 versus 2, 3 or
linear mixed model; MTA, medial temporal lobe atrophy.Contrary to what was expected, there was no differ-
ence in body weight between patients with moderate,
severe or very severe MTA, neither at the time of diag-
nosis, nor during the course of the disease. Moreover,
during follow-up, a time period in which the severity of
MTA is expected to increase, patients did not lose but
gained weight. Therefore, we reject the hypothesis that
weight loss is associated with MTA. As far we know,
four other studies investigated the relation of brain path-
ology with nutritional status in AD patients [22,26-28].
Contrary to our finding, Grundman et al. showed that
MTA was associated with low body weight in AD pa-
tients [22]. In addition, Burns et al. showed that a higher
BMI was associated with less brain atrophy [27]. This as-
sociation, however, was modest [27]. Hu et al. found no
association between a low BMI and the medial temporal
lobe [26], which is in line with our finding that there
was no difference in body weight between patients with
moderate, severe or very severe MTA. Ho et al. reported
that more severe hippocampal atrophy was associated
with a higher BMI in patients with mild AD [28], which
confirms our result that patients with moderate, severe
or very severe MTA weighed more than patients with no
or mild MTA. These results also underline the findings4 (results from the univariate GLMM analyses). GLMM, generalized
Table 5 Patient characteristics at baseline: left MTA score of 0 or 1 versus 2, 3 or 4
MTA score 0 or 1 MTA score 2, 3, 4 P
Age (year): n, median [25th -75th percentile] 16, 75.0 [72.0 - 78.8] 198, 79.0 [75.8 - 82.0] 0.003b**
Women, n (%) 11 (68.8) 121 (61.1) nsc
Social status
alone, n (%) 10 (62.5) 83 (43.5) nsc
with partner, n (%) 5 (31.3) 103 (53.9)
other*, n (%) 1 (6.3) 5 (2.6)
CIRS (score): n, median [25th -75th percentile] 16, 5.0 [4.0 - 6.0] 198, 6.0 [4.0 - 8.0] nsb
Polypharmacy, n (%) 8 (50.0) 105 (53.3) nsc
Use of informal care, n (%) 13 (81.3) 169 (85.8) nsd
Use of professional care, n (%) 6 (37.5) 93 (47.7) nsc
MMSE (score): n, median [25th -75th percentile] 16, 25.0 [23.0 - 26.8] 196, 23.0 [20.0 - 15.0] 0.017b**
Clock-drawing test (score): n, median [25th -75th percentile] 15, 3.0 [1.0 - 4.0] 178, 3.0 [2.0 -5.0] nsb
Presence of BPS, n (%) 5 (31.3) 46 (23.8) nsd
Weight (kg): n, mean ± SD 16, 68 ± 12 198, 74 ± 12 nsa
BMI (weight/(height)2): n, median [25th -75th percentile] 16, 25.7 [21.1 - 27.0] 187, 25.9 [23.5 - 29.1] nsb
Use of ONS, n (%) 0 (0.0) 1 (0.8) nsd
Appetite
good, n (%) 14 (87.5) 156 (93.4) nsd
poor, n (%) 2 (12.5) 11 (6.6)
Self-reported weight loss, n (%) 2 (12.5) 26 (14.6) nsd
*Other, that is: with son or daughter, brother or sister; **significant, that is P <0.05. aIndependent sample t test; bMann-Whitney U test; cPearson chi-square test;
dFisher’s exact.
MTA, medial temporal lobe atrophy; P, probability; n, number of patients; ns, not significant; CIRS, cumulative illness rating scale; MMSE, mini mental state
examination; BPS, behavioral and psychological symptoms; SD, standard deviation; BMI, body mass index; ONS, oral nutritional supplement.
Droogsma et al. Alzheimer's Research & Therapy  (2015) 7:18 Page 7 of 11of Gustafson et al. [48] and Ward et al. [49]. Gustafson
et al. investigated the longitudinal relationship between
BMI and MTA in a cohort of middle-aged women
during 24 years of follow-up [48]. The average BMI of
women who developed MTA was higher at all examina-
tions than women who did not develop MTA [48]. In
the same cohort, a higher BMI was associated with a
higher incidence of dementia, particularly AD [2]. It is
suggested that this latter relationship could be explained
by the fact that being overweight is a risk factor for
hypertension, type 2 diabetes, and cardiovascular dis-
eases, all of which have been shown to increase the risk
of AD [50]. Though, it is also possible that being over-
weight increases the risk of AD by directly affecting theTable 6 Trajectory of weight per right MTA score (results from
n MTA score 0 or 1 MTA score 2
mean weight (95% CI) mean weight
Baseline 214 70.12 (64.46 - 75.78) 74.23 (62.49 - 8
6 months 194 70.48 (63.13 - 77.82) 74.11 (58.86 - 8
18 months 160 68.06 (59.85 - 76.27) 74.56 (57.52 - 9
30 months 116 70.79 (62.24 - 79.33) 75.43 (57.70 - 9
MTA, medial temporal lobe atrophy; GLMM, generalized linear mixed model; n, numneurodegenerative process in the brain [50]. Ward et al.
performed a cross-sectional study to investigate the rela-
tionship between BMI and brain atrophy in middle-aged
(40 to 66 years) adults [49]. A higher BMI was associated
with more severe brain atrophy, though BMI was not asso-
ciated with cognitive function [49].
It must be taken into consideration that comparison
of our study with the aforementioned studies has to be
performed cautiously, because of differences in patient
characteristics and study methodology. For example, pa-
tients in the study of Grundman et al. and Burns et al.
were not treated with a ChEI. In addition, the severity
of AD varied with mean MMSE score in the study of
Grundman et al. of 19 [18], in the study of Burns et al.the univariate GLMM analyses)
MTA score 3 MTA score 4
(95% CI) mean weight (95% CI) mean weight (95% CI)
5.98) 73.03 (61.10 - 84.97) 78.62 (64.70 - 92.54)
9.36) 72.13 (56.63 - 87.63) 77.51 (59.43 - 95.60)
1,59) 73.12 (55.83 - 90.42) 80.07 (59.90 - 100.23)
3.16) 72.94 (54.92 - 90.95) 80.50 (59.22 - 101.77)
ber of remaining patients; CI, confidence interval.
Figure 3 Trajectory of weight per right MTA score (results from the univariate GLMM analyses). GLMM, generalized linear mixed model;
MTA, medial temporal lobe atrophy.
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all patients in the study of Gustafson et al. and Ward
et al. were diagnosed with AD at baseline [48,49]. More-
over, the way in which brain pathology was measured
differed. In the present study, brain atrophy was mea-
sured with MRI, Hu et al. investigated brain glucose me-
tabolism by positron emission tomography (PET) and
[18F]fluordeoxyglucose (FDG) [26], Ho et al. applied an
automated hippocampal mapping method to measure
hippocampal volume [28] and Grundman et al. per-
formed morphometric analysis to assess the severity of
MTA [22], while we used a visual rating scale to assess
MTA. These differences may have contributed to the
conflicting results. The conflicting results might also re-
flect variation in sample sizes, ranging from 27 [26] to
162 AD patients [28], versus 214 AD patients in the present
study. In addition, nutritional status was measured cross-
sectional in the mentioned studies [22,26-28], while we
measured weight longitudinally.
Our surprising finding that patients with more severe
MTA weighed more than patients with no or mild
MTA, has to be interpreted carefully since less than 10%
of the patients from our cohort had a MTA score of 0 or
1. The representativeness of patients with no or mild
MTA in our cohort is unclear. As expected, patientsTable 7 Trajectory of weight: right MTA 0 or 1 versus 2, 3 or
n MTA score 0 or 1 MTA sc
mean weight (95% CI) Δ Weigh
Baseline 214 70.12 (64.42 - 75.81)
6 months 194 70.48 (63.09 - 77.87) 0.36
18 months 160 68.06 (59.80 - 76.32) −2.42
30 moths 116 70.79 (62.17 - 79.40) 2.74
MTA, medial temporal lobe atrophy; GLMM, generalized linear mixed model; n, numwith no or mild MTA had a higher baseline MMSE
score and were less dependent than patients with mod-
erate, severe or very severe MTA [25]. Though, despite
the fact that these patients had no or only mild MTA,
they were referred to the memory clinic. There are no
data on the weight of patients with a MTA score of 0
or 1 who were not referred to a memory clinic. It cannot
be ruled out that these patients have a higher body
weight than the patients with a MTA score of 0 or 1 who
presented at our memory clinic.
Some limitations of the present study must be consid-
ered when interpreting the findings. Since we only inves-
tigated the relationship between MTA and body weight,
it cannot be ruled out that pathology of other brain re-
gions or other forms of brain pathology are associated
with the trajectory of body weight in AD patients. In
addition, our study was performed in a selected group of
patients (that is they had an indication for a MRI scan
and were all treated with a ChEI), which may have con-
tributed to some degree of selection bias. ChEIs appear
to slow the progression of hippocampal atrophy by 1.2%
a year [51]. It cannot be ruled out that the ChEIs slowed
the progression of hippocampal atrophy, thereby pre-
venting weight loss mediated by MTA. Whether a delay
of 1.2% a year is enough to prevent weight loss and even4 (results from the univariate GLMM analyses)
ore 0 or 1 MTA score 2, 3, 4 MTA score 2, 3, 4
t mean weight (95% CI) Δ Weight
74.12 (62.49- 85.75)
73.62 (58.53 - 88.72) −0.5
74.43 (57.57- 91.30) 0.81
74.88 (57.28 - 92.47) 0.45
ber of remaining patients; CI, confidence interval.
Figure 4 Trajectory of weight; right MTA score 0 or 1 versus 2, 3 or 4 (results from the univariate GLMM analyses). GLMM, generalized
linear mixed model; MTA, medial temporal lobe atrophy.
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that patients that lost weight were more frequently ‘lost
to follow-up’ inducing a bias. However, all subjects were
patients receiving care in accordance with the standard-
ized treatment protocol, which included regular visits toTable 8 Patient characteristics at baseline: right MTA score of
MT
Age (year): n, median [25th -75th percentile] 17
Women, n (%) 9 (
Social status
alone, n (%) 8 (
with partner, n (%) 9 (
other*, n (%) 0 (
CIRS (score): n, median [25th -75th percentile] 17
Polypharmacy, n (%) 7 (
Use of informal care, n (%) 11
Use of professional care, n (%) 5 (
MMSE (score): n, median [25th -75th percentile] 17
Clock-drawing test (score): n, median [25th -75th percentile] 16
Presence of BPS, n (%) 3 (
Weight (kg): n, mean ± SD 17
BMI (weight/(height)2): n, median [25th -75th percentile] 15
Use of ONS, n (%) 0 (
Appetite
good, n (%) 16
poor, n (%) 0 (
Self reported weight loss, n (%) 0 (
*Other, that is: with son or daughter, brother or sister; **significant, that is P <0.05.
dFisher’s exact.
MTA, medial temporal lobe atrophy; P, probability; n, number of patients; ns, not sig
examination; BPS, behavioral and psychological symptoms; SD, standard deviation;our clinic. Although bias cannot fully be excluded, we
think that the extent of this kind of bias is negligible
since the main reason for the reduced number of
subjects in our longitudinal analysis is the timing of
entering the care program. In this, patients differ in the0 or 1 versus 2, 3 or 4
A score 0 or 1 MTA score 2, 3, 4 P
, 73.0 [72.0 - 79.0] 197, 79.0 [76.0 - 82.0] 0.003b**
52.9) 123 (62.4) nsc
47.1) 85 (44.7) nsc
52.9) 99 (52.1)
0. 0) 6 (3.2)
, 5.0 [4.0 - 6.5] 197, 6.0 [4.0 - 8.0] nsb
41.2) 106 (54.1) nsc
(64.7) 171 (87.2) 0.022d**
29.4) 94 (48.5) nsc
, 25.0 [22.0 - 27.5] 195, 23.0 [20.0 - 25.0] 0.026b**
, 3.0 [1.0 - 4.0] 177, 3.0 [2.0 - 5.0] nsb
17.7) 48 (25.0) nsd
, 70 ± 11 197, 74 ± 12 nsa
, 25.6 [21.5 - 27.0] 188, 25.9 [23.5 - 28.9] nsb
0.0) 1 (0.6) nsd
(100) 154 (92.2) nsd
0.0) 13 (7.8)
0.0) 28 (15.8) nsd
aIndependent sample t test; bMann-Whitney U test; cPearson chi-square test;
nificant; CIRS, cumulative illness rating scale; MMSE, mini mental state
BMI, body mass index; ONS, oral nutritional supplement.
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than patients leave the program due to disease-related
causes. Another limitation is the absence of data regard-
ing the trajectory of weight before the diagnosis AD
was made. Weight loss may be a preclinical feature of
AD [44,52]. Perhaps, weight loss in patients from our
cohort may have occurred before they were referred to
the memory clinic. In addition, the association between
MTA and the trajectory of weight change could depend
on disease severity at baseline as measured with the
MMSE. Unfortunately, we did not have enough patients
to stratify by MMSE or to do a sensitivity analysis.
Moreover, MTA was measured cross-sectionally, instead
of longitudinally. Therefore, it was not possible to inves-
tigate whether percent change in MTA over time pre-
dicts weight change, nor to elucidate whether weight
loss causes disease progression by aggravating MTA. In
addition, it was not possible to elucidate patterns of
MTA atrophy. These patterns are, unfortunately, not
fully elucidated by other studies [25]. Because of the
retrospective nature of the study, we were dependent on
data collected in the past. As a consequence, some data
was not available, for instance information on appetite
measured with a valid scale and information on dietary
intake. In addition, we could not adjust for all known
factors associated with weight loss, such as caregiver
burden [53].
To the best of our knowledge, this is the largest study
examining the relationship between MTA and the trajec-
tory of weight change in AD patients, and the only
study in which body weight was measured longitudinally.
Another strength of the study is the use of the GLMM.
Statistical analysis of longitudinal data is complicated
because of interdependency of measurements and, par-
ticular in older AD patients, drop out of patients [54].
The GLMM is specifically developed for the analysis of
longitudinal-dependent data. All data contribute to the
longitudinal analysis and even data from patients who
dropped out can be used. This way we could include a
large number of patients with a long length of follow-up.
Moreover, the severity of MTA was scored independently
by two raters. The agreement between the raters was fair
to good, and better than the interobserver agreement of
Scheltens et al., which was fair [37].
Conclusions
We found no evidence that atrophy of the medial temporal
lobe is associated with weight loss in AD patients. Moreover,
contrary to what was expected, AD patients did not lose but
gained weight during follow-up.
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